The Value of Urinary NGAL, KIM-1, and IL-18 Measurements in the Early Detection of Kidney Injury in Oncologic Patients Treated with Cisplatin-Based Chemotherapy
-
Published:2024-01-16
Issue:2
Volume:25
Page:1074
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Szumilas Dawid1ORCID, Owczarek Aleksander Jerzy2ORCID, Brzozowska Aniceta2, Niemir Zofia Irena3ORCID, Olszanecka-Glinianowicz Magdalena2, Chudek Jerzy12ORCID
Affiliation:
1. Department of Internal Diseases and Oncological Chemotherapy, Faculty of Medicine in Katowice, Medical University of Silesia in Katowice, 40-027 Katowice, Poland 2. Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medicine in Katowice, Medical University of Silesia in Katowice, 40-055 Katowice, Poland 3. Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznań, Poland
Abstract
Cisplatin is still a widely used anticancer drug characterized by significant nephrotoxicity. Acute kidney injury (AKI), diagnosed based on the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, has limitations, including a delayed increase in creatinine. We determined the usefulness of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) in diagnosing AKI according to the KDIGO criteria in patients treated with cisplatin. We recruited 21 subjects starting cisplatin-based chemotherapy (Cisplatin-based group) and 11 treated with carboplatin-based chemotherapy or 5-fluorouracil regimens (non-cisplatin-based group). Blood and urine samples were collected during four subsequent cycles of chemotherapy (68 and 38 cycles, respectively). AKI occurred in four patients in the cisplatin-based group (5.9% of 68 cisplatin-based chemotherapy cycles). Among them, three urinary markers were increased by over 100% in two cases, two in one case and one in another. A doubling of at least one investigated parameter was observed more frequently during cisplatin-based chemotherapy (80.3% vs. 52.8%; OR = 3.65, 95% CI: 1.49–8.90; p < 0.01). The doubling of at least one new urinary AKI marker was more common in patients receiving cisplatin and frequently was not associated with overt AKI. Thus, a subclinical kidney injury detected by these markers occurs more frequently than deterioration in kidney function stated with creatinine changes.
Funder
Medical University of Silesia
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference64 articles.
1. Volarevic, V., Djokovic, B., Jankovic, M.G., Harrell, C.R., Fellabaum, C., Djonov, V., and Arsenijevic, N. (2019). Molecular Mechanisms of Cisplatin-Induced Nephrotoxicity: A Balance on the Knife Edge between Renoprotection and Tumor Toxicity. J. Biomed. Sci., 26. 2. Oka, T., Kimura, T., Suzumura, T., Yoshimoto, N., Nakai, T., Yamamoto, N., Matsuura, K., Mitsuoka, S., Yoshimura, N., and Kudoh, S. (2014). Magnesium Supplementation and High Volume Hydration Reduce the Renal Toxicity Caused by Cisplatin-Based Chemotherapy in Patients with Lung Cancer: A Toxicity Study. BMC Pharmacol. Toxicol., 15. 3. Nephroprotective Effects of Hydration with Magnesium in Patients with Cervical Cancer Receiving Cisplatin;Yamamoto;Anticancer Res.,2015 4. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury;Eknoyan;Kidney Int. Suppl.,2012 5. Neutrophil Gelatinase-Associated Lipocalin in Normal and Neoplastic Human Tissues. Cell Type-Specific Pattern of Expression;Friedl;Histochem. J.,1999
|
|